Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEStastic: [18F]FES PET Imaging in Metastatic ER+ Breast Cancer
NCT05088785Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fluoroestradiol f 18 in breast cancer (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: FES uptake in lesions: Ki (net influx rate) or VT (volume of distribution) values at 1 year. Started Oct 2021; status: active, not recruiting.
02
Drugs
fluoroestradiol f 18
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05088785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088785.